PDGFRB and neoplasm: It rapidly reorganizes the tumor’s microvascular architecture by inhibiting targets like VEGFR2 and PDGFRβ, thus mitigating tumor hypoxia and improving the effectiveness of radiotherapy in eliminating hypoxic cells (19).